Live Updates: COVID-19 Cases
  • World 30,408,365
    Confirmed: 30,408,365
    Active: 7,364,431
    Recovered: 22,092,455
    Death: 951,479
  • USA 6,877,617
    Confirmed: 6,877,617
    Active: 2,519,418
    Recovered: 4,155,933
    Death: 202,266
  • India 5,228,478
    Confirmed: 5,228,478
    Active: 1,018,231
    Recovered: 4,125,742
    Death: 84,505
  • Brazil 4,457,443
    Confirmed: 4,457,443
    Active: 569,330
    Recovered: 3,753,082
    Death: 135,031
  • Russia 1,091,186
    Confirmed: 1,091,186
    Active: 170,784
    Recovered: 901,207
    Death: 19,195
  • Peru 750,098
    Confirmed: 750,098
    Active: 124,439
    Recovered: 594,513
    Death: 31,146
  • Mexico 684,113
    Confirmed: 684,113
    Active: 123,518
    Recovered: 488,416
    Death: 72,179
  • South Africa 655,572
    South Africa
    Confirmed: 655,572
    Active: 54,497
    Recovered: 585,303
    Death: 15,772
  • Spain 625,651
    Confirmed: 625,651
    Active: 595,246
    Recovered: ?
    Death: 30,405
  • Chile 441,150
    Confirmed: 441,150
    Active: 15,080
    Recovered: 413,928
    Death: 12,142
  • Iran 416,198
    Confirmed: 416,198
    Active: 36,741
    Recovered: 355,505
    Death: 23,952
  • France 415,481
    Confirmed: 415,481
    Active: 293,546
    Recovered: 90,840
    Death: 31,095
  • UK 381,614
    Confirmed: 381,614
    Active: 339,909
    Recovered: ?
    Death: 41,705
  • Bangladesh 345,805
    Confirmed: 345,805
    Active: 88,589
    Recovered: 252,335
    Death: 4,881
  • Saudi Arabia 328,720
    Saudi Arabia
    Confirmed: 328,720
    Active: 15,938
    Recovered: 308,352
    Death: 4,430
  • Pakistan 304,386
    Confirmed: 304,386
    Active: 6,295
    Recovered: 291,683
    Death: 6,408
  • Turkey 298,039
    Confirmed: 298,039
    Active: 26,979
    Recovered: 263,745
    Death: 7,315
  • Italy 293,025
    Confirmed: 293,025
    Active: 41,413
    Recovered: 215,954
    Death: 35,658
  • Germany 270,123
    Confirmed: 270,123
    Active: 19,361
    Recovered: 241,300
    Death: 9,462
  • Canada 140,867
    Confirmed: 140,867
    Active: 8,558
    Recovered: 123,109
    Death: 9,200
  • Netherlands 90,047
    Confirmed: 90,047
    Active: 83,774
    Recovered: ?
    Death: 6,273
  • China 85,255
    Confirmed: 85,255
    Active: 165
    Recovered: 80,456
    Death: 4,634
  • Australia 26,861
    Confirmed: 26,861
    Active: 2,169
    Recovered: 23,855
    Death: 837
  • S. Korea 22,783
    S. Korea
    Confirmed: 22,783
    Active: 2,635
    Recovered: 19,771
    Death: 377
  • New Zealand 1,809
    New Zealand
    Confirmed: 1,809
    Active: 70
    Recovered: 1,714
    Death: 25

IBM introduces cloud-based AI platform RoboRXN to accelerate drug synthesis

Author at TechGenyz Artificial Intelligence
IBM Pharmaceutical Laboratory
Credit: @sonson | Unsplash

Technological giant IBM has introduced a new AI platform called RoboRXN designed to support and assist scientists to discover and create new drugs in a shorter time-frame at reduced cost. As per the AI platform RoboRXN can be seen as a novel chemical laboratory running on cloud. It’s like a virtual chemical lab.

The addition of this AI platform will be a great help for researchers around the world. The usage of computing prowess and technical power to speed up the process of drug discovery has been looked into, especially in the present-day COVID-19 scenario. With the availability of a computational modeling platform, the very essential step of transitioning the experimental drugs from the trial stage to acceptance by the relevant regulatory bodies is expected to become faster and more efficient.

According to research conducted on drug production, IBM observes that it takes a total of 10 years on an average for a new drug to be discovered and be made available on the market for consumption. Also, the average funding for this amounts to at least 10 million dollars.

The tech giant aims to reduce the time taken to one year and also bring down the funding to around 1 million dollars. The usage of an AI platform to accelerate the drug synthesis process seems to be a good way to go about it.

IBM has made the RoboRXN for Chemistry a free AI service. Scientists or researchers can log in to it easily through a web browser. In this virtual laboratory they can draw the molecular structure of the compound they want to create. The AI platform then uses machine learning algorithms to determine the necessary composition and the mixing sequence to be followed.

RoboRXN helps the scientists by finding the most optimum scientific route and also guides them to the most appropriate commercially available material to be started with. Once these data have been submitted, RoboRXN executes the process and the report of the result is sent to the scientists.

According to tests conducted by IBM, RoboRNX offers a 90% accuracy rate in predicting chemical reaction. Given its high accuracy and ease of usage, RoboRNX can be of great value to commercial drug production sector. It can bring down the production costs and also help in large production in a short time.

At a time when the world requires an immediate vaccine for COVID-19, an AI chemical laboratory could be of a great boon for the scientists and help them in faster drug trials. IBM has launched multiple AI tools across areas related to drug discovery, drug, and disease information related information search during the COVID-19 pandemic. These have been made free for clinicians and researchers to use.

The company has launched its own Functional Genomics Platform. In addition to this it has also introduced two platforms called Micromedex and EBSCO DynaMed for making faster and more accurate inquiries on drugs and clinical disease information. These two platforms help medical professionals to gain access to wide range of content related to infectious diseases including COVID.

Furthering the application of technology in the pharmaceutical domain, IBM has also pushed its supercomputer Summit, installed in the Oak Ridge National Laboratory (ORNL) of the US Department of Energy, to tackle major challenges in the health sector.